
Impact
GenomeMET project will have a profound impact across several fields
For industrial and other user communities
​
-
IVD developers
-
Clinical laboratories
-
Healthcare providers
-
RM producers
-
EQA providers
-
Drug developers
-
Clinical researchers
-
Regulators

For the metrology and scientific communities
​
-
Improved NMI/DI capabilities for quantification of cancer genomic biomarkers, quantification of total nucleic acids, and detection of panels of genomic variants, demonstrated through inter-laboratory comparisons.
-
Dissemination of case studies to advance the development of metrological frameworks for multi-analyte clinical genomic profiling.
-
Submission of new RMP for quantification of cancer genomic biomarkers and SI-traceable RMs to JCTLM database.

For relevant standards
​
-
support for existing standards
-
input to the drafting of standards under development
-
proposal for new standards

Longer-term economic, social, and environmental impacts
​
-
reduces diagnostic errors, preventing missed or incorrect diagnoses
-
facilitates the administration of personalized treatments
-
improve patient outcomes
-
reduce healthcare costs
-
growth in the European in vitro diagnostics and oncology therapeutics markets
